352 related articles for article (PubMed ID: 19546864)
1. Quantitative imaging biomarkers in neuro-oncology.
Waldman AD; Jackson A; Price SJ; Clark CA; Booth TC; Auer DP; Tofts PS; Collins DJ; Leach MO; Rees JH;
Nat Rev Clin Oncol; 2009 Aug; 6(8):445-54. PubMed ID: 19546864
[TBL] [Abstract][Full Text] [Related]
2. Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy?
Heiland S; Wick W; Bendszus M
J Clin Oncol; 2010 Oct; 28(29):e591; author reply e592. PubMed ID: 20837945
[No Abstract] [Full Text] [Related]
3. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Valable S; Petit E; Roussel S; Marteau L; Toutain J; Divoux D; Sobrio F; Delamare J; Barré L; Bernaudin M
Nucl Med Biol; 2011 Aug; 38(6):781-93. PubMed ID: 21843775
[TBL] [Abstract][Full Text] [Related]
4. Advanced MR imaging of gliomas: an update.
Kao HW; Chiang SW; Chung HW; Tsai FY; Chen CY
Biomed Res Int; 2013; 2013():970586. PubMed ID: 23862163
[TBL] [Abstract][Full Text] [Related]
5. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
[TBL] [Abstract][Full Text] [Related]
6. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
7. Inclusion or exclusion of intratumoral vessels in relative cerebral blood volume characterization in low-grade gliomas: does it make a difference?
Caseiras GB; Thornton JS; Yousry T; Benton C; Rees J; Waldman AD; Jäger HR
AJNR Am J Neuroradiol; 2008 Jun; 29(6):1140-1. PubMed ID: 18388221
[TBL] [Abstract][Full Text] [Related]
8. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.
Jain R
NMR Biomed; 2013 Aug; 26(8):1042-9. PubMed ID: 23832526
[TBL] [Abstract][Full Text] [Related]
9. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation.
Toyooka M; Kimura H; Uematsu H; Kawamura Y; Takeuchi H; Itoh H
Clin Imaging; 2008; 32(4):251-8. PubMed ID: 18603178
[TBL] [Abstract][Full Text] [Related]
10. Functional and metabolic magnetic resonance imaging and positron emission tomography for tumor volume definition in high-grade gliomas.
Tsien CI; Cao Y; Lawrence TS
Semin Radiat Oncol; 2009 Jul; 19(3):155-62. PubMed ID: 19464630
[TBL] [Abstract][Full Text] [Related]
11. [Use of amino acid PET in the Diagnostic and Treatment Management of cerebral gliomas].
Galldiks N; Langen KJ
Fortschr Neurol Psychiatr; 2012 Jan; 80(1):17-23. PubMed ID: 22161228
[TBL] [Abstract][Full Text] [Related]
12. Characterization of untreated gliomas by magnetic resonance spectroscopic imaging.
Nelson SJ; McKnight TR; Henry RG
Neuroimaging Clin N Am; 2002 Nov; 12(4):599-613. PubMed ID: 12687914
[TBL] [Abstract][Full Text] [Related]
13. Imaging biomarkers in primary brain tumours.
Lopci E; Franzese C; Grimaldi M; Zucali PA; Navarria P; Simonelli M; Bello L; Scorsetti M; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):597-612. PubMed ID: 25520293
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of arterial spin labeling.
Watts JM; Whitlow CT; Maldjian JA
NMR Biomed; 2013 Aug; 26(8):892-900. PubMed ID: 23378178
[TBL] [Abstract][Full Text] [Related]
15. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.
Law M; Cha S; Knopp EA; Johnson G; Arnett J; Litt AW
Radiology; 2002 Mar; 222(3):715-21. PubMed ID: 11867790
[TBL] [Abstract][Full Text] [Related]
16. Predicting grade of cerebral glioma using vascular-space occupancy MR imaging.
Lu H; Pollack E; Young R; Babb JS; Johnson G; Zagzag D; Carson R; Jensen JH; Helpern JA; Law M
AJNR Am J Neuroradiol; 2008 Feb; 29(2):373-8. PubMed ID: 17974612
[TBL] [Abstract][Full Text] [Related]
17. Dynamic susceptibility contrast MRI of gliomas.
Aronen HJ; Perkiö J
Neuroimaging Clin N Am; 2002 Nov; 12(4):501-23. PubMed ID: 12687908
[TBL] [Abstract][Full Text] [Related]
18. [Neuroimaging in brain tumors].
Arbizu J; Domínguez PD; Diez-Valle R; Vigil C; García-Eulate R; Zubieta JL; Richter JA
Rev Esp Med Nucl; 2011; 30(1):47-65. PubMed ID: 21211868
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility-Weighted Imaging of Glioma: Update on Current Imaging Status and Future Directions.
Hsu CC; Watkins TW; Kwan GN; Haacke EM
J Neuroimaging; 2016 Jul; 26(4):383-90. PubMed ID: 27227542
[TBL] [Abstract][Full Text] [Related]
20. Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review.
Oltra-Sastre M; Fuster-Garcia E; Juan-Albarracin J; Sáez C; Perez-Girbes A; Sanz-Requena R; Revert-Ventura A; Mocholi A; Urchueguia J; Hervas A; Reynes G; Font-de-Mora J; Muñoz-Langa J; Botella C; Aparici F; Marti-Bonmati L; Garcia-Gomez JM
Curr Med Imaging Rev; 2019; 15(10):933-947. PubMed ID: 32008521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
